Industry Presses EU To Agree Medicines Deal With UK
Pharma Firms ‘Extremely Concerned’ Over Lack Of Progress In Talks
A letter addressed to EU leaders has urged them to prioritize the preservation of supply chains and access to medicines for patients in both the UK and the EU as worries grow over the sluggish pace of talks on a trade deal.
You may also be interested in...
The UK’s departure from the EU imposes a number of requirements on sponsors running EU trials, but it seems that many have still not taken steps to fall into line.
UK proposals for limited cooperation with the EU in medicines regulation, including the recognition of certificates and inspections, are one glimmer of light in an otherwise uncertain post-Brexit regulatory scenario for the UK. But time pressures and political spats over the future relationship could throw the whole enterprise into doubt.
With efforts continuing to maximize access to medical countermeasures against the pandemic threat, a webinar organized by NGOs looked at progress with and the shortcomings of the WHO’s C-TAP initiative, recent moves by the WHO on access provisions in funding agreements, and plans for a global C-TAP database.